Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Bavarian Nordic A/S

News headline image
Bavarian Nordic Reports Strong First Half 2026 Results
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Receives European Commission Approval of Mpox/Smallpox Vaccine for Children Aged 2 to Less than 12 Years
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Consortium Led by Nordic Capital and Permira Will Make All-Cash Recommended Purchase Offer for Bavarian Nordic
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Announces FDA Acceptance and Priority Review of the BLA for its Chikungunya Vaccine
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Receives USD 156.8 Million from the U.S. Government for Additional Smallpox/Mpox Vaccine Production
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to EMA
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines Agency
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus Vaccine in Adults and Adolescents
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Receives USD 120 Million Contract for the Manufacturing of Smallpox and Mpox Vaccine from the U.S. Government
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic to Acquire Portfolio of Travel Vaccines from Emergent BioSolutions
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Enters Agreement Valued up to USD 83 Million with the U.S. Department of Defense to Further Advance the Development of Equine Encephalitis Virus Vaccine
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults
From Bavarian Nordic A/S
Via GlobeNewswire
News headline image
Bavarian Nordic’s COVID-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial
From Bavarian Nordic A/S
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.